

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Vergnault *et al.*

CONFIRMATION NO.: 3745

APPLICATION NO.: 10/538,344

EXAMINER: YOUNG, SHAWQUIA

FILING DATE: June 9, 2005

ART UNIT: 1626

FOR: TOPICAL NANOPARTICULATE SPIRONOLACTONE
FORMULATION

VIA EFS

INFORMATION DISCLOSURE STATEMENT


Applicant hereby directs the Examiner's attention to the references A4-A19, B11-B21 and C3 listed on the attached form entitled "Information Disclosure Statement by Applicant." Copies of references B11-B21 and C3 are included.

The following application discloses and claims subject matter related to the instant application and has common co-inventors: US 2008/0069886.

This Information Disclosure Statement is being submitted after the mailing of a first Office action on the merits but before the mailing date of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the above identified application. Authorization for payment of the fee set forth in 37 C.F.R. § 1.17(p) accompanies the filing of this paper.

Respectfully submitted,

Date: January 20, 2011



David E. Johnson, Reg. No. 41,874
Mueli Liberto, Reg. No. 55,382
Attorneys for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623